KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus (OTCQB: PVCT) today provided an update on the Company's small molecule clinical development program for its investigational immuno-dermatology drug PH-10 for the treatments of psoriasis and atopic dermatitis. Pathways significantly improved by PH-10 use include published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22, and interferons.
Provectus has begun work in support of extended 12-week administration (proof-of-concept or POC) for topically applied, non-steroidal PH-10:
PH-10's mechanism of action (MOA), as well as its implications for immunology, are beginning to be understood. James Krueger, MD, PhD and members of the Laboratory for Investigative Dermatology at The Rockefeller University have elucidated PH-10's MOA for psoriasis in a previous clinical study (NCT02322086).
A clinical study of PH-10's MOA for atopic dermatitis is planned for 2019, and would be undertaken by a different dermatology and immunology investigator.
Dominic Rodrigues, Vice Chair of the Company's Board of Directors, said, "PH-10 is a clinical-stage, multi-indication viable, and immuno-dermatology-capable pharmaceutical asset. It has a novel mechanism of action; exhibits attractive preliminary safety and efficacy properties; has compelling product, manufacturing, and pricing characteristics; and is based on a family of small molecules entirely and wholly owned by Provectus. We are committed to properly monetizing this important asset for shareholders by developing PH-10 into a Phase 3-ready candidate, for both psoriasis and atopic dermatitis, in an efficient, effective, and industry-recognized manner."
Provectus' investigational dermatology drug, PH-10, a topically applied, non-steroidal, small molecule-based gel, is undergoing clinical study for inflammatory dermatoses like psoriasis and atopic dermatitis. PH-10 is self-applied to affected skin with photoactivation via ambient exposure to visible light.
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company leading the development of a new class of drugs for oncology and dermatology based on a family of molecules called halogenated xanthenes. The Company's lead investigational cancer drug product, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017).
Provectus Biopharmaceuticals, Inc.
Tim Scott, Ph.D.